AstraZeneca and MSD’s Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation

 AstraZeneca and MSD’s Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation

Shots:

  • The P-III PROfound study involves assessing of Lynparza (olaparib) vs Enzalutamide/Abiraterone in men with mCRPC and have progressed on prior treatment with anti-cancer therapies with HRRm gene mutation
  • The P-III PROfound study resulted in meeting its 1EPs i.e, improvement in radiographic PFS in men with mCRPC selected for BRCA1/2 or ATM gene mutations, safety & tolerability profiles were consistent with the previous study 
  • Lynparza is a PARP inhibitor act by blocking DNA damage response in tumors harboring HRR mutation including BRCA1/BRCA2. AstraZeneca and MSD are also evaluating Lynparza for prostate cancer and as a 1L therapy in ongoing P-III PROpel study in combination with abiraterone for mCRPC

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Life Sciences IP Review

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post